A5047390098- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Platelet Disorders and Treatments
- Wound Healing and Treatments
- Heparin-Induced Thrombocytopenia and Thrombosis
- Mesenchymal stem cell research
- Blood groups and transfusion
- Eosinophilic Disorders and Syndromes
- Autoimmune Bullous Skin Diseases
- Blood disorders and treatments
- 3D Printing in Biomedical Research
- Acute Myeloid Leukemia Research
- Chronic Lymphocytic Leukemia Research
- Extracellular vesicles in disease
- Chronic Myeloid Leukemia Treatments
- Venous Thromboembolism Diagnosis and Management
- Multiple Myeloma Research and Treatments
University of Palermo
2024-2025
University of Bologna
2022-2023
Istituto di Ematologia di Bologna
2022-2023
Istituti di Ricovero e Cura a Carattere Scientifico
2023
Abstract Background Patients with cytopenic myelofibrosis (MF) have more limited therapeutic options and poorer prognoses compared patients the myeloproliferative phenotype. Aims Methods Prognostic correlates of phenotype were explored in 886 ruxolitinib‐treated primary/secondary MF (PMF/SMF) included RUX‐MF retrospective study. Cytopenia was defined as: leukocyte count <4 × 10 9 /L and/or hemoglobin <11/<10 g/dL (males/females) platelets <100 /L. Results Overall, 407 (45.9%) had...
Diabetic foot ulcers (DFUs) are chronic wounds and a common complication of diabetes. A promising strategy in the treatment DFUs involves use stem cell derivatives, such as small extracellular vesicles (sEVs), which can enhance proliferation reduce inflammation while avoiding immunogenic responses. In this study, we evaluated ability adipose mesenchymal cell- (ASC)-derived sEVs to human fibroblasts, play crucial role wound regenerative processes. To mimic inflammatory environment DFUs,...
Platelet-rich plasma (PRP) is a product of significant interest in the field regenerative medicine due to its healing, immunomodulatory and anti-inflammatory properties. Although role remains debated, PRP has undeniably shown considerable potential aiding healing various injuries pathologies across multiple fields, from dermatology (e.g., hair loss, skin scars) reproductive inflammatory diseases osteoarthritis). The aim this review summarise describe treating common musculoskeletal athletes....
Fostamatinib is a SYK-inhibitor drug recently approved by the FDA and EMA for treating chronic immune thrombocytopenia. This induces response in about 40% of patients has good toxicity profile. It known that discontinuing thrombopoietin receptor agonists (TRAs) with maintenance sustained off therapy possible. On fostamatinib, we do not yet have such information. In this case report, describe story woman multirefractory thrombocytopenia (steroids, splenectomy, rituximab, both available TRAs)....
Several infections and vaccinations can provoke immune thrombocytopenia (ITP) onset or relapse. Information on ITP epidemiology management during the Covid-19 pandemic is scarce. In a large monocenter cohort, we assessed incidence risk factors for: 1) onset/relapse after Covid19 vaccination/infection; 2) infection.Information date/type of anti-Covid-19 vaccine, platelet count before within 30 days from date/grade was collected via phone call hematological visits. relapse defined as drop in...
Background: Pregnancy (P) might trigger or exacerbate a pre existing Immune thrombocytopenia (ITP). A substantial risk of maternal bleeding at delivery (D), side effects ITP treatment (tx), the neonate and worsening disease lasting after D are possible consequences related to P. Specific evidence-based guidelines lacking in this setting suggestions about management derived from non-pregnant population. Moreover data efficacy safety tx limited P, especially for thrombopoietin receptor...